Navigation Links
VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
Date:7/30/2009

BEDFORD, Mass., July 30 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that scientists reporting in the July 31 issue of SCIENCE have discovered a key disease-related biologic pathway using an integrated and innovative array of in vitro readouts and advanced in vivo imaging technologies. The newly reported biologic pathway relates to monocyte deployment from the spleen to inflammatory sites, including myocardial infarction. The findings are expected to open up new areas of research and potentially advance therapeutic approaches to key disease areas including inflammation and myocardial injury.

In the SCIENCE report, entitled "Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites," researchers at the Massachusetts General Hospital's Center for Systems Biology found that monocytes were held in concentration in the spleen and released to injured tissue sites in the body to participate in wound healing. As presented in the findings, the reporting scientists discovered and detailed the biologic pathway through the use of a series of advanced and integrated in vitro assays, microscopic readouts, and in vivo imaging methodologies, including Magnetic Resonance (MR) imaging combined with quantitative Fluorescence Molecular Tomographic (FMT) imaging. Used together in a series of novel scientific models, the researchers developed correlated data sets to both identify this previously unidentified splenic reservoir of monocytes, and demonstrate the monocyte deployment to inflammatory sites in vivo. In the in vivo data analysis, non-invasive, quantitative FMT imaging using novel fluorescent molecular imaging agents, combined with MR imaging, clearly demonstrated not only the location, but also the biological activity of the recruited splenic monocytes at the disease site, thus helping to confirm "unambiguously the fate of monocytes from the spleen to the heart."

"We see the integration of in vitro and in vivo readouts becoming increasingly important in research today, and we are extremely pleased that our FMT quantitative in vivo imaging technology and activatable in vivo imaging agents were able to help the research team answer some of the key questions about this important biologic pathway in vivo," said Dr. Jeffrey Peterson, VP, Applied Biology at VisEn Medical. "When cardiac molecular imaging data from the FMT was combined with MRI imaging, the researchers were able to create a fused molecular and anatomical imaging map of the heart to identify and quantify biomarkers of monocyte activity in vivo. These results enabled an important data correlation that further enhanced the integrated array of in vitro assays and microscopy-based readouts of this important pathway."

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
3. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
4. Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
5. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
6. Midwest Research Institute Launches Clinical Molecular Diagnostics Laboratory
7. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
8. Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State
9. Verification Studies of IntelligentMDxs Proprietary Molecular Diagnostic Assay Process Have Been Completed
10. Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source
11. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... ... 2017 , ... PurhealthRX , a leading Health and Nutrition Company, is ... to full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing ... easily incorporated into liquid products, while reducing costs to end users. , The team ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
Breaking Medicine News(10 mins):